• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

The SOLAR-1 trial: alpelisib prolongs progression free survival in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients

byDayton McMillan
May 22, 2019
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer patients who have a mutated phosphatidylinositol 3-kinase (PIK3) with the PIK3 inhibitor alpelisib, in addition to fulvestrant, increased progression free survival compared to treatment with fulvestrant alone.

2. The most common severe adverse effects in alpelisib-fulvestrant treated patients were hyperglycemia and rash.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Over 70% of breast cancers are HR-positive, HER2-negative, and almost half of those patients have mutations in the PIK3 gene. Endocrine therapy is standard treatment for these patients, but many develop resistance to treatment. Endocrine therapy paired with the PIK3 inhibitor alpelisib has shown promise in prior phase 1 and 2 trials, and in the current study is compared to standard endocrine therapy in a phase 3 trial. Patients with HR-positive, HER2-negative, PIK3-mutated cancer profiles treated with combination therapy had significantly longer progression-free survival times compared to those treated with endocrine therapy alone. In patients without a mutated PIK3 gene, progression free survival was similar between treatments. Common adverse events experiences by alpelisib treated patients included hyperglycemia and rash.

This phase 3 trial provides strong evidence for an altered standard of treatment among patients with a specific breast cancer genetic profile who have failed prior endocrine therapy. Study strengths include treatment of patients with and without PIK3 mutations and its extensive subgroup analysis. The study is limited by its relatively short follow-up time not presently allowing for strong overall survival analysis.

Click to read the study in NEJM

RELATED REPORTS

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts

Relevant Reading: Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

In-Depth [randomized controlled trial]: This phase 3, double-blind, randomized, international, placebo-controlled trial enrolled patients between 2015 and 2017. Men and post-menopausal women with locally confirmed HR-positive, HER2-negative breast cancer and were eligible to receive further endocrine therapy after having progression or relapse following initial endocrine therapy treatment. Those who had previously received chemotherapy, fulvestrant therapy, or been treated with PI3K, AKT, or mTOR inhibitors were excluded from participating. Patients with and without PI3K mutations were recruited for the study. For each cohort of patients with (n=341) or without (n=231) a PI3K mutation, patients were randomly assigned to alpelisib-fulvestrant or placebo-fulvestrant groups. After a median of 20 months follow-up, the primary outcome of progression-free survival in patients with a PIK3-mutation was 11.0 and 5.7 months in the combination and placebo-fulvestrant groups, respectively (hazard ratio for progression or death [HR], 0.65; 95% confidence interval [CI], 0.50 to 0.85; P<0.001). Overall therapy response for those with a PIK3-mutation was greater in the combination therapy group (26.6% vs. 12.8%). For patients without a PIK3-mutation median survival time was 7.4 and 5.6 months in the combination and placebo-fulvestrant groups, respectfully (HR, 0.85; 95% CI, 0.58 to 1.25). Serious adverse events occurring in the combination therapy group, as compared to the placebo-fulvestrant group, included hyperglycemia (36.6% vs 0.7%) and rash (9.9% and 0.3%).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: alpelisibBreast Cancerfulvestrantphosphatidylinositol 3-kinase (PIK3)PIK3 inhibitor
Previous Post

Lipid profiles of US youth improving over last two decades

Next Post

Quick Take: Body composition and cardiovascular events in patients with colorectal cancer

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Chronic Disease

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

July 2, 2025
3D mammography (tomosynthesis) enhances accuracy of breast cancer screening
Chronic Disease

Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts

June 25, 2025
#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
StudyGraphics

#VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

June 17, 2025
Next Post
Development of a risk index for colorectal cancer screening

Quick Take: Body composition and cardiovascular events in patients with colorectal cancer

Little variation seen in readmission rates between primary care physicians in Texas

No survival benefit with ICDs in non-ischemic systolic heart failure: The DANISH trial

The WRAP-IT trial: antibiotic-eluting envelope covering implanted cardiac devices lowers incidence of major injections

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes
  • Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
  • Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.